Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
Alexi Vasbinder(University of Washington), Salim S. Hayek(Emory University), Monika Leja(University of Michigan), Sarah Yentz(University of Michigan), Leslie A. Fecher(University of Pennsylvania), Elizabeth Anderson(University of Michigan), Bryan J. Schneider(Georgetown University), Sarah Adie(University of Michigan), YeeAnn Chen(University of Michigan), Pennelope Blakely(University of Michigan), Adrien Procureur(Sorbonne Université), Husam Shadid(University of Michigan), Marie Bretagne(Sorbonne Université), Tonimarie Catalan(University of Michigan), Kristen Pogue(University of Michigan), Mohamad Fardous(University of Michigan), Allison Gradone(University of Michigan), Joe‐Elie Salem(Inserm), Daniel Perry(University of Michigan), Namratha Nelapudi(University of Michigan), Christopher D. Lao(University of Michigan), Tariq U. Azam(University of Michigan)
Cited by 78
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
|Science Translational Medicine|2011|637
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560